Skip to content
Sign in

IBRX · NASDAQ

ImmunityBio (IBRX) Stock Price & Fundamentals

$362.56+0.63%+$2.26End-of-day price as of Oct 9, 2026

ImmunityBio (IBRX) closed at $362.56 on Oct 9, 2026, up 0.63% from the previous close of $360.30.

Share price, past year

1Y +0.05%

52-week range $323.83 – $376.36. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$362.56
Sep 30, 2026$360.86
Aug 31, 2026$366.31
Jul 31, 2026$351.17
Jun 30, 2026$334.90
May 29, 2026$337.35
Apr 30, 2026$332.97
Mar 31, 2026$337.12
Feb 27, 2026$347.83
Jan 30, 2026$347.97
Dec 31, 2025$356.84
Nov 28, 2025$352.23
Oct 31, 2025$369.94

Key statistics

Market cap
$381.86B
P/E (TTM)
—
EPS (TTM)
−$0.97
Revenue (TTM)
$165.79M
Net income (TTM)
−$992.36M
Shares outstanding
1.1B
Dividend yield
—
52-week range
$323.83 – $376.36

ImmunityBio's market cap is $381.86B, based on a share price of $362.56 and 1.1B shares outstanding as of Jun 30, 2026.

Financials

ImmunityBio reported revenue of $113.29M for fiscal 2025, up 668.31% from fiscal 2024.

ImmunityBio reported a net loss of $351.40M in fiscal 2025.

Fiscal 2025 revenue was the highest in the 10 years shown.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
ImmunityBio annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$113.29M+668.3%−$351.40M−310.2%−$0.38−$308.78M
FY2024ended Dec 31, 2024$14.75M+2,270.6%−$413.56M−2,804.8%−$0.62−$398.12M
FY2023ended Dec 31, 2023$622.00K+159.2%−$583.20M−93,761.4%−$1.15−$397.34M
FY2022ended Dec 31, 2022$240.00K−74.3%−$416.57M−173,569.6%−$1.04−$415.67M
FY2021ended Dec 31, 2021$934.00K+54.4%−$346.79M−37,129.6%−$0.89−$307.98M
FY2020ended Dec 31, 2020$605.00K−72.5%−$221.85M−36,669.6%−$0.59−$173.39M
FY2019ended Dec 31, 2019$2.20M+4,585.1%−$157.78M−7,165.2%−$0.43−$156.40M
FY2018ended Dec 31, 2018$47.00K+4.4%−$96.23M−204,736.2%−$1.22−$76.48M
FY2017ended Dec 31, 2017$45.00K+2.3%−$96.42M−214,273.3%−$1.20−$83.60M
FY2016ended Dec 31, 2016$44.00K—−$120.81M−274,565.9%−$1.47−$45.15M
ImmunityBio quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$51.24M−$230.38M−$0.22
Q1 FY2026ended Mar 31, 2026$44.21M−$632.78M−$0.62
Q4 FY2025ended Dec 31, 2025$38.29M−$61.94M−$0.06
Q3 FY2025ended Sep 30, 2025$32.06M−$67.25M−$0.07
Q2 FY2025ended Jun 30, 2025$26.43M−$92.56M−$0.10
Q1 FY2025ended Mar 31, 2025$16.52M−$129.65M−$0.15
Q4 FY2024ended Dec 31, 2024$7.55M−$59.16M−$0.08
Q3 FY2024ended Sep 30, 2024$6.11M−$85.73M−$0.14

Company profile

Name
ImmunityBio, Inc.
Ticker
IBRX
Exchange
NASDAQ
Industry (SEC SIC)
Biological Products, (No Diagnostic Substances)
Headquarters
3530 John Hopkins Court, San Diego, CA 92121
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001326110

Recent SEC filings

Frequently asked questions

What is ImmunityBio's stock price?

ImmunityBio (IBRX) closed at $362.56 on Oct 9, 2026, up 0.63% from the previous close of $360.30.

What is ImmunityBio's market cap?

ImmunityBio's market cap is $381.86B, based on a share price of $362.56 and 1.1B shares outstanding as of Jun 30, 2026.

How much revenue does ImmunityBio make?

ImmunityBio reported revenue of $113.29M for fiscal 2025, up 668.31% from fiscal 2024.

Does ImmunityBio pay a dividend?

ImmunityBio's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from ImmunityBio, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures